Patent: 10,004,812
✉ Email this page to a colleague
Summary for Patent: 10,004,812
Title: | Antibody-drug conjugates and immunotoxins |
Abstract: | The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed. |
Inventor(s): | Kontermann; Roland (Nurtingen, DE), Pfizenmaier; Klaus (Tiefenbronn, DE), Ferrer; Cristina (Madrid, ES), Fabre; Myriam (Barcelona, ES), Simon; Laureano (Derio, ES) |
Assignee: | Oncomatryx Biopharma, S.L. (Derio, ES) |
Application Number: | 15/116,419 |
Patent Claims: | see list of patent claims |
Details for Patent 10,004,812
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2034-02-06 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-02-06 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-02-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |